Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
RIVM launches new web-based version of ConsExpo An improved version of the computer program ConsExpo is now available via the RIVM website.
Livestock farming affects pulmonary function in local residents COPD patients living near livestock farms suffer more complications.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
More people infected with diseases transmitted by wild rodents In 2014, there were more patients in the Netherlands with diseases transmitted by wild rodents than in previous years.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
The number of STI tests keeps increasing The number of clients tested for sexually transmitted infections (STIs) at Dutch STI clinics has increased since 2004.